A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 118, Issue 9, Pages e2016072118
Publisher
Proceedings of the National Academy of Sciences
Online
2021-02-18
DOI
10.1073/pnas.2016072118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Does protein aggregation drive postmitotic tissue degeneration?
- (2021) Jeffery W. Kelly Science Translational Medicine
- Neurofilament light chain (NfL) as a biomarker of hereditary transthyretin-mediated amyloidosis
- (2020) Simina Ticau et al. NEUROLOGY
- Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials
- (2019) Joel N. Buxbaum AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis
- (2019) Mahima Kapoor et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis
- (2019) Matthias Schmidt et al. Nature Communications
- Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin
- (2018) Jacquelyn L.S. Hanson et al. Circulation-Heart Failure
- Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
- (2018) Hartmut H. Schmidt et al. MUSCLE & NERVE
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- (2018) David Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Drugs for Transthyretin Amyloidosis
- (2018) Joel N. Buxbaum NEW ENGLAND JOURNAL OF MEDICINE
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
- (2018) Mathew S. Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy
- (2018) Teresa Coelho et al. NEUROLOGY
- Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis
- (2017) Ana Martins da Silva et al. JOURNAL OF NEUROLOGY
- Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
- (2017) Andrea Cortese et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Sural nerve injury in familial amyloid polyneuropathy
- (2017) Jennifer Kollmer et al. NEUROLOGY
- Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
- (2017) Joseph D. Schonhoft et al. Science Translational Medicine
- Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
- (2016) Márcia Waddington Cruz et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe
- (2016) David Adams CURRENT OPINION IN NEUROLOGY
- Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis
- (2016) Yoshiki Sekijima et al. NEUROLOGY
- Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
- (2016) D. Adams et al. REVUE NEUROLOGIQUE
- Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures
- (2016) Sunil M. Kurian et al. Theranostics
- Liver transplantation in transthyretin amyloidosis: Issues and challenges
- (2015) Andreia Carvalho et al. LIVER TRANSPLANTATION
- Targeting protein aggregation for the treatment of degenerative diseases
- (2015) Yvonne S. Eisele et al. NATURE REVIEWS DRUG DISCOVERY
- Liver Transplantation for Hereditary Transthyretin Amyloidosis
- (2015) Bo-Göran Ericzon et al. TRANSPLANTATION
- Plasma Transthyretin as a Biomarker of Lean Body Mass and Catabolic States
- (2015) Yves Ingenbleek et al. Advances in Nutrition
- Repurposing Diflunisal for Familial Amyloid Polyneuropathy
- (2015) John L. Berk et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography
- (2014) Jennifer Kollmer et al. BRAIN
- CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings
- (2014) L. F. Maia et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
- (2013) Teresa Coelho et al. JOURNAL OF NEUROLOGY
- Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
- (2013) Teresa Coelho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
- (2012) T. Coelho et al. NEUROLOGY
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
- (2012) C. E. Bulawa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atomic View of a Toxic Amyloid Small Oligomer
- (2012) Arthur Laganowsky et al. SCIENCE
- Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival
- (2009) Sadahisa Okamoto et al. LIVER TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started